Global Alcohol Use Disorder Market to 2030 - Insight, Epidemiology and Market Forecast -

·4-min read

The "Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to's offering.

The market size of Alcohol Use Disorder is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Alcohol Use Disorder market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 78.19 million, while Italy had the smallest market size of USD 9.29 million.

The Alcohol Use Disorder market report provides analysis regarding current treatment practices, approved therapies including Acamprosate (Campral), Disulfiram (Antabuse) and Naltrexone (Revia), emerging drugs like Ibudilast, AD04, TNX-102 SL market share of the individual therapies, and historical, current and forecasted Alcohol Use Disorder market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Alcohol Use Disorder treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Alcohol use disorder (AUD) is a chronic heritable brain disorder with a variable clinical presentation. This variability, or heterogeneity, in clinical presentation, suggests complex interactions between environmental and biological factors, resulting in the development and progression of AUD. Classifying AUD into subgroups of common clinical or pathological characteristics would ease the complexity of teasing apart underlying molecular mechanisms.

Alcohol use disorder is characterized by loss of control over alcohol drinking that is accompanied by changes in brain regions related to the execution of motivated behaviors and the control of stress and emotion. Mechanisms of positive and negative reinforcement both play imperative roles with individual drinking behavior being maintained by positive reinforcement (rewarding and desirable effects of alcohol) and/or negative reinforcement mechanisms.

Report Highlights:

  • In the coming years, Alcohol Use Disorder market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.

  • The in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Alcohol Use Disorder market

  • To understand the future market competition in the Alcohol Use Disorder market and Insightful review of the key market drivers and barriers

  • Organize sales and marketing efforts by identifying the best opportunities for Alcohol Use Disorder in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan

  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

  • Organize sales and marketing efforts by identifying the best opportunities for Alcohol Use Disorder market

  • To understand the future market competition in the Alcohol Use Disorder market

Key Topics Covered:

1 Key Insights

2 Executive Summary of Alcohol Use Disorder (AUD)

3 SWOT Analysis for Alcohol Use Disorder (AUD)

4 Alcohol Use Disorder (AUD) Market Overview at a Glance

4.1 Market Share (%) Distribution of AUD in 2017

4.2 Market Share (%) Distribution of AUD in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Definitions

5.3 Causes and risk factors

5.4 Subtypes of Alcoholics

5.5 Pathophysiology

5.6 Genetics of AUD

5.7 Diagnosis

5.8 Biomarkers

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Diagnosed Prevalent Population of Alcohol Use Disorder (AUD)

7 Country Wise-Epidemiology of Alcohol Use Disorder

7.1 The United States

7.2 EU-5

7.3 Japan

8 Treatment of AUD

8.1 Guidelines

8.1.1 American Psychiatric Association Guidelines

8.1.2 NICE Guidelines

8.2 Case study: Naltrexone for the Management of Alcohol Dependence

8.3 Patient Journey

9 Unmet Needs

10 Marketed Therapies

10.1 Acamprosate: Merck sante

10.2 Disulfiram: Odyssey pharmaceuticals

10.3 Naltrexone: Dupont

11 Emerging Therapies

11.1 Ibudilast: MediciNova

11.2 AD04: Adial Pharmaceuticals

11.3 TNX-102: Tonix Pharmaceuticals

12 Alcohol Use Disorder: 7 Major Market Analysis

12.1 Key Findings

12.2 Market Outlook:7MM

12.3 Market Size of Alcohol Use Disorder (AUD) in 7MM

12.4 United States

12.4.1 Total Market size of Alcohol Use Disorder (AUD)

12.4.2 Alcohol Use Disorder (AUD) Market Size by Therapies

12.5 EU5 Countries

12.5.1 Germany

12.5.2 France

12.5.3 Italy

12.5.4 Spain

12.5.5 United Kingdom

12.5.6 Japan

13 Market Drivers

14 Market Barriers

15 Appendix

15.1 Report Methodology

16 Publisher Capabilities

17 Disclaimer

18 About the Publisher

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting